Georgia Public Broadcasting featured a story this week about how the Syn-One Test helped Dr. Daniel Cobb, owner of The Neuro Center in Gainesville, Georgia, provide a diagnosis to Chris Griffin, a patient who was experiencing troubling and unexplained symptoms.
The California-based drug development company FAScinate Therapeutics, Inc. announced positive results from the first part of a Phase 2 trial of KM-819, a compound
being tested for the treatment of Parkinson’s disease.
The FDA announced that it will lift the full Clinical Hold on IkT-148009, a c-Abl tyrosine kinase inhibitor that has shown promising results at stopping the progression of Parkinson’s disease in animal models.
Ambroxol, the active ingredient in cough syrup, is set to enter a Phase 3 clinical trial early this year in patients with Parkinson’s disease.
Previous research has demonstrated that mutations in the SCNA gene, a gene responsible for the production of alpha-synuclein, are associated with an aggressive form of Parkinson’s disease.
CND Life Sciences, an innovative medical diagnostics company pioneering the detection, visualization, and quantification of protein deposition in cutaneous nerve fibers, has been awarded a $4.2 million grant from the Arizona Governor’s Office to support the creation of the world’s first digital biosignatures laboratory focused on neurodegenerative disorders.
Previous estimates of the incidence of Parkinson’s disease have varied for reasons that are not completely understood but may be attributable to the location of the study, small sample sizes, or how cases were defined.
Dr. Toni De Marcaida, Medical Director of Hartford Healthcare’s Chase Family Movement Disorders Center in Hartford, CT, spoke this week on WFSB Channel 3 News about the positive impact the Syn-One Test has had on her practice and patients. “This is a test that has never been available to us as clinicians before.”
1ST Biotherapeutics, Inc., announced positive results from a Phase 1 trial of FB-101, an investigational compound being studied to treat Parkinson’s disease and other neurodegenerative disorders.
New research published in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association last month demonstrated that patients show declines in cognition, grip strength, and overall health up to several years before being diagnosed with a neurodegenerative disorder.